Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Gilead Sciences stock heads into Denver meeting with liver data

Clinical trial results Company update Drug approval AI-generated analysis

πŸ“… Gilead Sciences will present 21 abstracts on primary biliary cholangitis and chronic hepatitis delta at The Liver Meeting 2026 in Denver from November 5 to 9.

πŸ”¬ A late-breaking Phase 3 presentation from the IDEAL study will evaluate seladelpar (Livdelzi) focusing on alkaline phosphatase normalization in adults with lower levels of elevation.

⏳ The company will present longer-term safety and efficacy evidence for seladelpar through five years of treatment during the conference.

🩺 Gilead plans to address fatigue as a key symptom affecting quality of life for patients with primary biliary cholangitis in its scientific program.

πŸ“Š Additional analyses will examine factors affecting eligibility for second-line treatment, adherence, and healthcare use for Livdelzi.

🦠 The company will present long-term and real-world evidence for Hepcludex, including a 96-week analysis of combined virologic and biochemical response.

🩸 A separate presentation will cover a 48-week analysis of clinically significant portal hypertension in people receiving Hepcludex treatment.

πŸ“‰ Gilead Sciences stock traded at 150.78 euros on November 2, 2026, representing a 2.29 percent decline from the previous Friday's close.

πŸ’° The company's market capitalization was reported at approximately 187.6 billion euros as of November 2, 2026.

Bullish Signals
  • Gilead Sciences will present late-breaking Phase 3 results from the IDEAL study evaluating seladelpar (Livdelzi) in adults with primary biliary cholangitis.
  • The company is set to present longer-term safety and efficacy evidence for seladelpar through five years of treatment at the upcoming conference.
  • Gilead will showcase a 96-week analysis of combined virologic and biochemical response for its hepatitis delta treatment, Hepcludex.
Full Analysis
Gilead Sciences is preparing to present new clinical and real-world evidence regarding its rare liver disease portfolio at The Liver Meeting 2026 in Denver, scheduled from November 5 to 9. The company has announced a program featuring 21 accepted abstracts focused on primary biliary cholangitis (PBC) and chronic hepatitis delta, marking the next major catalyst for its liver business following recent market activity. The core of the presentation strategy involves late-breaking Phase 3 results from the IDEAL study evaluating seladelpar, marketed as Livdelzi. This specific presentation on November 8 will examine composite alkaline phosphatase normalization in adults with lower levels of elevation who were taking or unable to tolerate ursodeoxycholic acid, alongside five-year safety and efficacy data. In addition to PBC updates, Gilead plans to showcase long-term evidence for Hepcludex, its treatment for chronic hepatitis delta virus infection. The program includes a 96-week analysis of combined virologic and biochemical response and a 48-week analysis of clinically significant portal hypertension, aiming to highlight the need for earlier detection and stronger long-term disease management in this rare disease space.